LBT Innovations (ASX:LBT) - Managing Director & CEO, Brent Barnes
Managing Director & CEO, Brent Barnes
Source: LBT Innovations
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) has outlined a new board policy for its Non-Executive Directors
  • Under the new policy, directors will apply a salary sacrifice of 25 per cent to purchase new LBT shares
  • The policy will be in place until each Non-Executive Director has invested an amount equal to a full year’s gross directors’ fee
  • Thats said, the policy is still subject to shareholder approval
  • On market close for the weekend, LBT is up 7.14 per cent and is trading at 10.5 cents per share

LBT Innovations (LBT) has outlined a new board policy for its Non-Executive Directors.

Under the new policy, directors will apply a salary sacrifice of 25 per cent to purchase new LBT shares.

The LBT Board knows the importance of having directors invested in the future performance of the company, which is why the new board policy has been put in place.

LBT believes the new policy will represent an ongoing commitment from all Non-Executive Directors.

The policy will be in place until each Non-Executive Director has invested an amount equal to a full year’s gross directors’ fee.

However, the policy is subject to shareholder approval. If approved, new LBT shares will be issued within one month of the annual general meeting.

“This new board policy sets a commitment to ensure all directors invest in, and support, the future of LBT Innovations,” Chairman Kate Costello said.

“This is a positive indication of the long term potential the board see in the company and builds alignment between the LBT Board and feedback received from LBT shareholders,” he added.

On market close for the weekend, LBT is up 7.14 per cent and is trading at 10.5 cents per share.

LBT by the numbers
More From The Market Online

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…

Little Green Pharma closely eyeing USA’s legal downgrade of Cannabis danger

Overnight, the Biden government did something sure to give their counterparts a stir – the USA…

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…